152 related articles for article (PubMed ID: 24521310)
1. Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.
Fenstermaker RA; Ciesielski MJ
Expert Rev Vaccines; 2014 Mar; 13(3):377-85. PubMed ID: 24521310
[TBL] [Abstract][Full Text] [Related]
2. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.
Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD
Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
[TBL] [Abstract][Full Text] [Related]
4. Glioma-specific antigens for immune tumor therapy.
Skog J
Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
[TBL] [Abstract][Full Text] [Related]
5. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
J Neurooncol; 2016 Dec; 130(3):517-527. PubMed ID: 27624914
[TBL] [Abstract][Full Text] [Related]
7. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
8. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Normolle DP; Connelly AK; Dibridge S; Mason G; Whiteside TL; Okada H
Neuro Oncol; 2016 Aug; 18(8):1157-68. PubMed ID: 26984745
[TBL] [Abstract][Full Text] [Related]
9. Glioma antigen.
Toda M
Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
[TBL] [Abstract][Full Text] [Related]
10. Peptide vaccine.
Izumoto S
Adv Exp Med Biol; 2012; 746():166-77. PubMed ID: 22639167
[TBL] [Abstract][Full Text] [Related]
11. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
14. Peptide-based immunotherapeutic approaches to glioma: a review.
Yamanaka R; Itoh K
Expert Opin Biol Ther; 2007 May; 7(5):645-9. PubMed ID: 17477802
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
de Vleeschouwer S; Rapp M; Sorg RV; Steiger HJ; Stummer W; van Gool S; Sabel M
Neurosurgery; 2006 Nov; 59(5):988-99; discussioin 999-1000. PubMed ID: 17143233
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of experimental active specific immunotherapy and immunoprevention of malignant gliomas of the brain].
Romodanov SA; Zatula DG; Lisianyĭ NI; Glavatskiĭ AIa; Prosvirneva GM
Zh Vopr Neirokhir Im N N Burdenko; 1986; (3):18-23. PubMed ID: 3739492
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
18. [Anti-glioma vaccination].
Delhaye M; Clavreul A; Garcion E; Menei P
Neurochirurgie; 2003 Sep; 49(4):459-63. PubMed ID: 14526258
[No Abstract] [Full Text] [Related]
19. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
[TBL] [Abstract][Full Text] [Related]
20. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
